HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

8- (2- (2- pentyl- cyclopropylmethyl)cyclopropyl)octanoic acid

Also Known As:

8-DCP-LA; DCP-LA

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Caprylates: 33
      - 8-(2-(2-pentyl-cyclopropylmethyl)cyclopropyl)octanoic acid: 4
Lipids: 114793
- Fatty Acids: 27405
  - Caprylates: 33
    - 8-(2-(2-pentyl-cyclopropylmethyl)cyclopropyl)octanoic acid: 4

Experts

1.	Nishizaki, Tomoyuki: 3 articles (07/2012 - 05/2010)
2.	Kanno, Takeshi: 2 articles (07/2012 - 01/2011)
3.	Shimizu, Tadashi: 2 articles (07/2012 - 01/2011)
4.	Tanaka, Akito: 2 articles (07/2012 - 01/2011)
5.	Yaguchi, Takahiro: 2 articles (07/2012 - 05/2010)
6.	Alkon, Daniel L: 1 article (01/2011)
7.	Hongpaisan, Jarin: 1 article (01/2011)
8.	Sun, Miao-Kun: 1 article (01/2011)
9.	Fujikawa, Hirokazu: 1 article (05/2010)

Related Diseases

1.	Memory Disorders (Memory Loss) 07/01/2012 - "The present study examined the effect of racemic and diastereomeric DCP-LA on age-related learning and memory disorders using accelerated-senescence-prone mice 8 (SAMP8) and accelerated-senescence-resistant mice 1 (SAMR1). "
2.	Amyloid Plaque 01/12/2011 - "Similarly, the PKC ε-specific activator, DCP-LA, effectively prevents synaptic loss, amyloid plaques, and cognitive deficits (also prevented by bryostatin-1) in the much more rapidly progressing 5XFAD transgenic strain. "
3.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 05/01/2010 - "For a mouse model of middle cerebral artery occlusion, oral administration with DCP-LA (1 mg/kg) significantly diminished degraded area due to cerebral infarction. "
4.	Neurodegenerative Diseases (Neurodegenerative Disease) 01/01/2011 - "This suggests that α, β-DCP-LA could be developed as a promising drug for treatment of not only dementia but neurodegenerative diseases and psychiatric disorders due to reduction/deficiency of neurotransmitters."
5.	Dementia (Dementias) 01/01/2011 - "This suggests that α, β-DCP-LA could be developed as a promising drug for treatment of not only dementia but neurodegenerative diseases and psychiatric disorders due to reduction/deficiency of neurotransmitters."

Related Drugs and Biologics

1.	Neurotransmitter Agents (Neurotransmitter)
2.	bryostatin 1

Related Therapies and Procedures

1.	Oral Administration